Health Care & Life Sciences » Biotechnology | biOasis Technologies Inc.

biOasis Technologies Inc. | Income Statement

Fiscal year is March-February. All values CAD Thousands.
2014
2015
2016
2017
2018
2019
Sales/Revenue
-
-
369.10
513.00
589.80
1,422
Cost of Goods Sold (COGS) incl. D&A
52.80
51.50
475.10
480.30
524.30
73.80
Gross Income
52.80
51.50
106.00
32.60
65.50
1,348.20
SG&A Expense
3,585.10
2,788.80
2,458.00
3,018.40
5,342.70
6,205.40
EBIT
3,638.00
2,840.30
2,564.00
2,985.80
5,277.30
4,857.20
Unusual Expense
-
2.10
-
-
-
981.80
Non Operating Income/Expense
3.00
17.60
16.60
10.50
42.00
400.20
Pretax Income
3,610.10
2,836.30
2,572.90
2,990.80
5,307.90
3,473.40
Consolidated Net Income
3,610.10
2,836.30
2,572.90
2,990.80
5,307.90
3,473.40
Net Income
3,610.10
2,836.30
2,572.90
2,990.80
5,307.90
3,473.40
Net Income After Extraordinaries
3,610.10
2,836.30
2,572.90
2,990.80
5,307.90
3,473.40
Net Income Available to Common
3,610.10
2,836.30
2,572.90
2,990.80
5,307.90
3,473.40
EPS (Basic)
0.09
0.07
0.06
0.07
0.10
0.06
Basic Shares Outstanding
40,835.30
42,976.30
44,436.50
45,415.60
50,901.40
56,675.20
EPS (Diluted)
0.09
0.07
0.06
0.07
0.10
0.06
Diluted Shares Outstanding
40,835.30
42,976.30
44,436.50
45,415.60
50,901.40
56,675.20
EBITDA
3,585.20
2,788.80
2,512.70
2,935.30
5,218.40
4,785.20
Non-Operating Interest Income
30.80
19.50
7.70
5.50
11.30
1.80

About biOasis Technologies

View Profile
Address
14 Water Street
Guilford Connecticut 06437
United States
Employees -
Website http://www.bioasis.ca
Updated 07/08/2019
biOasis Technologies, Inc. is a biopharmaceutical company focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include Transcend program as its proprietary carrier, p97, and components thereof, to deliver therapeutics and imaging agents across the blood brain barrier. The company was founded by Rob Hutchison on May 3, 2007 and is headquartered in Vancouver, Canada.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.